← The library
Livagen
Lys-Glu-Asp-Ala tetrapeptideGI/Bone/OtherEvidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
PurposeHepatic bioregulator
MechanismShort peptide from the Khavinson bioregulator family, reverse-engineered from liver tissue and proposed to act through tissue-selective gene regulation.
EffectsStudied for hepatic gene expression. Evidence is preclinical and mechanistic, largely from a single research group.
DosingNo human dose established.
Bottom lineOrgan-specific claims resting on one research tradition, with no Western clinical validation.
Batches on filenone
No tested batches on file.
Read with
The library records no pairings for this entry.
Cautions & interactions
The evidence base is Russian observational and preclinical work characterised from 1973 onwards. Independent Western clinical trials are essentially absent, so neither efficacy nor a safety profile has been established to the standard the rest of this catalog uses.
No interaction data published.
CV 1 of 5 — No controlled cardiovascular data.